Is HUMDF or NOBL a better dividend investment in 2026?

HUMDF currently yields 484.14% with a 5% 5-year dividend growth rate. NOBL yields 2.17% with 5% growth. The better choice depends on your goal: HUMDF offers higher current income.

What is the dividend yield difference between HUMDF and NOBL?

HUMDF has a forward dividend yield of 484.14% ($2.00/share annually). NOBL yields 2.17% ($2.27/share annually). The yield gap is 481.97 percentage points.

Home › Compare › HUMDF vs NOBL

HUMDF vs NOBL: Dividend Comparison 2026

HUMDF yields 484.14% · NOBL yields 2.17%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 HUMDF wins by $47899.99M in total portfolio value

INVESTMENT

TIME HORIZON10 years

HUMDF

● Live price

484.14%

Share price

$0.41

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$47900.01M

Annual income

$34,060,653,223.60

Full HUMDF calculator →

NOBL

● Live price

2.17%

Share price

$104.67

Annual div

$2.27

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.9K

Annual income

$249.78

Full NOBL calculator →

Portfolio growth — HUMDF vs NOBL

📍 HUMDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	HUMDF	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, HUMDF + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

HUMDF pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HUMDF

Annual income on $10K today (after 15% tax)

$41,152.26/yr

After 10yr DRIP, annual income (after tax)

$28,951,555,240.06/yr

NOBL

Annual income on $10K today (after 15% tax)

$184.52/yr

After 10yr DRIP, annual income (after tax)

$212.31/yr

At 15% tax rate, HUMDF beats the other by $28,951,555,027.75/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HUMDF + NOBL for your $10,000?

HUMDF: 50%NOBL: 50%

100% NOBL50/50100% HUMDF

Portfolio after 10yr

$23950.02M

Annual income

$17,030,326,736.69/yr

Blended yield

71.11%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HUMDF buys

NOBL buys

No recent congressional trades found for HUMDF or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricHUMDFNOBL

Forward yield	484.14% ✓	2.17%
Annual dividend / share	$2.00	$2.27 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$47900.01M ✓	$22.9K
Annual income after 10y	$34,060,653,223.60 ✓	$249.78
Total dividends collected	$46687.76M ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: HUMDF vs NOBL ($10,000, DRIP)

Year	HUMDF Portfolio	HUMDF Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$59,114	$48,414.43	$10,917	$217.08	+$48.2K → HUMDF
2	$330,728	$267,475.81	$11,903	$221.48	+$318.8K → HUMDF
3	$1,752,431	$1,398,551.73	$12,962	$225.68	+$1.74M → HUMDF
4	$8,800,812	$6,925,711.29	$14,099	$229.68	+$8.79M → HUMDF
5	$41,922,789	$32,505,919.38	$15,319	$233.49	+$41.91M → HUMDF
6	$189,569,894	$144,712,509.91	$16,628	$237.10	+$189.55M → HUMDF
7	$814,403,207	$611,563,420.90	$18,033	$240.53	+$814.39M → HUMDF
8	$3,326,842,984	$2,455,431,552.18	$19,539	$243.78	+$3326.82M → HUMDF
9	$12,933,979,587	$9,374,257,594.32	$21,154	$246.86	+$12933.96M → HUMDF
10	$47,900,011,382	$34,060,653,223.60	$22,884	$249.78	+$47899.99M → HUMDF

HUMDF vs NOBL: Complete Analysis 2026

HUMDF — Stock

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.

Full HUMDF Calculator →

NOBL — ETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →

📬

Get this HUMDF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HUMDF vs SCHD HUMDF vs JEPI HUMDF vs O HUMDF vs KO HUMDF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.